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I
 
n this issue of 
 
The Journal of Experimental Medicine
 
, Hud-
son et al. (1) report on the identification of a cytokine,
 
the macrophage migration inhibitory factor or MIF, that
overcomes p53 function by suppressing its transcriptional
activity, thus linking complex programs that govern proin-
flammatory response and cell fate. p53 has a key role in the
regulation of cell growth and death, and its involvement in
these regulatory systems may reflect its ability to respond to
different cellular stress situations by inducing cell cycle ar-
 
rest or apoptosis (see references 2–4 for reviews on the topic
and below for more details on p53 function). When altered
by germ line or somatic mutations, by aberrant patterns of
expression, or through the inactivating potential of Mdm2
or certain viral oncoproteins, loss of wild-type p53 function
 
is responsible for tumorigenesis and tumor progression (5–7).
The relationship between certain chronic inflammatory con-
ditions and cancer has been known for many years, and sev-
eral postulates have been furnished to explain such an asso-
ciation (for recent reviews see references 8 and 9). The study
of Hudson et al. provides a mechanistic connection between
chronic inflammation and tumorigenesis.
The authors used two independent functional screens to
isolate genes bypassing p53-mediated growth arrest or apop-
tosis, which both yielded cDNAs encoding MIF. Three dif-
ferent biological assays were then pursued to assess p53 sta-
tus after treatment with MIF. MIF was either directly tested
by transducing it into different cells or, as MIF was origi-
nally characterized as an extracellular cytokine, it was added
as a soluble factor. These experiments revealed that p53 con-
tinues to possess the same microanatomical nuclear localiza-
tion and maintain similar levels of expression in control and
MIF-treated cells. However, MIF partially suppresses p53-
dependent transcriptional activity, as evidenced by the low
levels of p21, cyclin G1, and Mdm2 observed in treated ver-
 
sus untreated cells. In the presence of MIF, Hudson et al. also
observed suppression of apoptosis. Finally, murine fibro-
blasts treated with MIF have an extended life span, support-
 
ing the concept that MIF may, at least in part, overcome
cellular senescence.
It is known that during tissue damage, lymphocytes and
macrophages are recruited at sites of inflammation. MIF is
released from T cells and macrophages, contributing to en-
hanced T cell activation and increased antimicrobial func-
tions of macrophages. Besides these proinflammatory func-
tions, activated macrophages also release reactive oxygen
species. These, in turn, could induce macrophage apopto-
 
sis, which has been demonstrated to be p53 dependent.
Hudson et al. propose that in the presence of active inflam-
matory cells, MIF would create a protective antiapoptosis
feedback loop. In addition, overcoming p53 transactivation
properties within repairing tissues would limit damage re-
sponse and the loss of host cells. Cessation of inflammation
will restore normal MIF levels and reinstate physiological
conditions. However, chronic bypass of p53 key regulatory
functions could enhance proliferation, extend life span, create
a deficient response to genetic damage, and even allow ac-
cumulation of oncogenic mutations. Taken together, these
phenomena could lead to cellular transformation and tumor
development. Fig. 1 is a diagram illustrating this sequence
of events.
Based on the natural history of certain diseases and epi-
demiology studies, a strong association has been established
between particular chronic inflammatory conditions and
eventual tumor appearance (8–11). Fig. 1 summarizes some
of these related processes, which include chronic infections
 
(i.e., schistosomiasis and bladder cancer, 
 
Helicobacter pylori
 
 and
gastric cancer, and hepatitis C and hepatocellular carcinoma);
chronic tissue damage by chemical or physical agents (i.e.,
reflux esophagitis and esophageal cancer in Barrett’s syn-
drome and chronic pancreatitis and pancreatic carcinoma);
and disorders of uncertain etiology producing chronic in-
flammation (i.e., chronic nonspecific ulcerative colitis and
Crohn’s disease and colon cancer). For most of these pro-
cesses, a sequence of histopathological events has been de-
scribed (12). Continuous damage first appears to cause tissue
atrophy. This is followed by increased proliferative activity,
which is usually associated with “metaplasia,” a reversible
change in which a differentiated cell type is replaced by an-
other differentiated cell type. “Dysplasia” may then develop,
characterized by irregular proliferative changes that yield
atypical cells as part of a nonadaptive process. Dysplastic
changes are often found adjacent to foci of cancer.
The morphological alterations described above have been
related to unbalanced biological systems. A number of in-
dependent studies using clinical samples have shown that
cell turnover is affected by the inflammatory response. This
notion is supported by reports describing an increase in cell
death by apoptosis as an early response to infection and
 
continued inflammation. For example, 
 
H. pylori
 
 and certain
 
inflammatory mediators, such as TNF and IFN-
 
g
 
, have
been shown to regulate apoptosis of gastric epithelial cells
(13). As a consequence, atrophic changes could develop that 
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may be reversible if the inflammatory stimuli cease. The
continuous presence of MIF, together with the cell loss
produced in the atrophic tissues, may then trigger a prolif-
erative response by noncommitted epithelial cell precur-
sors. There are multiple studies that have revealed the in-
creased expression of the proliferative Ki-67 nuclear antigen
in reactive, nonneoplastic epithelial cells at sites of chronic
inflammation. For example, colorectal biopsies from patients
with ulcerative colitis, undergoing colonoscopic surveil-
lance for histopathological detection of dysplasia to select
patients at high risk for prophylactic colectomy, showed in-
creased Ki-67 staining in areas of reactive/regenerating ep-
ithelium (14). Moreover, certain studies have also disclosed
the association between dysplasia and detection of mutations
affecting critical genes, such as 
 
K-RAS
 
 in chronic pancre-
atitis tissues (15). Loss of heterozygosity (LOH) at tumor
suppressor gene loci such as 3p, 9p21, and 17p11 (where p53
maps at 17p11.3) has also been documented in nonneoplas-
tic mucosa from patients with chronic ulcerative colitis (16).
Taken together, increased proliferation and the production
of these molecular alterations may give rise to the morpho-
logical changes ascribed to dysplasia and lead to neoplastic
transformation.
In addition to the studies referred to above, the direct as-
sociation between MIF and cancer has also been documented
in several reports. Protein expression profiles in breast duc-
tal carcinoma versus normal breast tissue were analyzed by
two-dimensional gels (17). There were 32 spots highly ex-
pressed in all carcinoma samples, one of them being MIF.
 
In another study, differential display PCR was used to iso-
late genes that exhibited increased expression in prostatic
adenocarcinoma metastases versus primary prostatic tumors
(18). Three cDNA clones were identified, two correspond-
ing to genes that showed no homology to known database
sequences. The third cDNA was that of MIF. In a follow-up
study, this group of investigators used immunohistochem-
istry, ELISA, and Northern blot analysis to assess MIF ex-
pression on a variety of normal prostatic tissues and primary
and metastatic prostate tumors, as well as several prostate
cancer cell lines (19). MIF was localized to the glandular ep-
ithelium, and the most intense expression was identified in
metastatic carcinomas and in LNCaP cells.
Hudson et al. have now provided data showing that MIF
treatment of cells inhibits the expression of endogenous
downstream targets of p53, including p21 and bax (1). Fur-
thermore, they found that MIF treatment blocked p53
transactivation in a reporter assay in transiently transfected
cells (1). How does MIF cause this downregulation of p53?
p53 possesses the domains and properties of many other
transcriptional activators (2, 3). Its NH
 
2
 
 terminus contains a
strong acidic activation region that has been shown to in-
teract
 
 
 
in vitro with members of the general transcriptional
machinery such as TBP, TAFs and p300/CBP, as well as
with its negative regulator, Mdm2. The central “core” of
the protein, where the vast majority of tumor-derived mis-
sense mutations are detected, contains its sequence-specific
DNA binding domain, which recognizes sites located within
the vicinity of its downstream target genes, including p21,
Figure 1. Diagram illustrating the working hypothesis of Hudson et al. relating chronic inflammation, release of MIF, and continuous bypass of p53
function as it may relate to tumorigenesis. 
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cyclin G, and Mdm2. The COOH terminus contains a tet-
ramerization region and a highly basic region that can neg-
atively regulate DNA binding by the central core domain.
It is well documented that the p53 protein is extensively
modified by phosphorylation and acetylation (4). Such
modifications have been mapped at sites within the NH
 
2
 
-
and COOH-terminal portions of the protein, and a number
of studies have shown that certain modifications can affect
DNA binding and protein interactions of p53. Importantly,
there have been several reports in the past two years show-
ing that many of these sites are targets of complex signaling
pathways (4). Understanding the impact of modification of
p53 after DNA damage is still in an early stage. However,
although we now know that several sites can be inducibly
modified, it has also been demonstrated that p53 protein in
normal unstressed cells is phosphorylated at several sites
(20). It has been shown that unmodified, bacterially expressed
p53 protein binds DNA very poorly when compared with
p53 isolated from eukaryotic cells (21). Furthermore, it is
also clear that overexpression of p53 in mammalian cells, even
in the absence of DNA damage–induced activation, results
in a protein capable of inducing its downstream targets. Thus,
constitutive or basal modification of p53 may be a necessary
prerequisite for the protein to be functional in vivo. We
can imagine a number of scenarios by which MIF could
conceivably cause repression of p53, all of which are en-
tirely speculative at this point. First, normal nonstress-induced
modification of p53 protein may be affected by MIF treat-
ment. MIF signaling might repress key basal phosphoryla-
tion events or, alternately, induce a new modification(s) in
p53, which in either case somehow renders it unable to ac-
tivate transcription. Second, p53 has been shown to be acti-
vated by noncovalent modifiers such as Ref-1 and HMG-1,
which stimulate its DNA binding in vitro and transactiva-
tion in vivo (22). Perhaps MIF initiates a process that leads
to inactivation or loss of these (or other as yet unidentified)
p53 coactivators. Third, MIF may cause expression or acti-
vation of one or more factors that directly interact with p53
and prevent its binding to DNA or interactions with gen-
eral transcription factors. Whatever the mode by which
MIF represses the transactivation function of p53, elucida-
tion of this process will undoubtedly shed new light onto
both MIF and p53. It will also provide further knowledge
regarding the link between complex programs such as
those governing inflammatory responses and tumorigenesis.
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